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The delineation of putatively protective and immunogenic epitopes in vaccine candidate proteins constitutes
a major research effort towards the development of an effective malaria vaccine. By virtue of its role in the
formation of the immune clusters of merozoites, its location on the surface of merozoites, and its highly con-
served nature both at the nucleotide sequence level and the amino acid sequence level, the antigen which con-
tains repeats of acidic and basic residues (ABRA) of the human malaria parasite Plasmodium falciparum
represents such an antigen. Based upon the predicted amino acid sequence of ABRA, we synthesized eight
peptides, with six of these (AB-1 to AB-6) ranging from 12 to 18 residues covering the most hydrophilic regions
of the protein, and two more peptides (AB-7 and AB-8) representing its repetitive sequences. We found that all
eight constructs bound an appreciable amount of antibody in sera from a large proportion of P. falciparum
malaria patients; two of these peptides (AB-1 and AB-3) also elicited a strong proliferation response in pe-
ripheral blood mononuclear cells from all 11 human subjects recovering from malaria. When used as carrier-
free immunogens, six peptides induced a strong, boostable, immunoglobulin G-type antibody response in
rabbits, indicating the presence of both B-cell determinants and T-helper-cell epitopes in these six constructs.
These antibodies specifically cross-reacted with the parasite protein(s) in an immunoblot and in an immuno-
fluorescence assay. In another immunoblot, rabbit antipeptide sera also recognized recombinant fragments of
ABRA expressed in bacteria. More significantly, rabbit antibodies against two constructs (AB-1 and AB-5)
inhibited the merozoite reinvasion of human erythrocytes in vitro up to ;90%. These results favor further
studies so as to determine possible inclusion of these two constructs in a multicomponent subunit vaccine
against asexual blood stages of P. falciparum.
Plasmodium falciparum causes the most virulent kind of
malaria in humans and is almost exclusively responsible for all
malaria-related deaths in the world. Several parasite antigens
from the asexual erythrocytic stages, such as merozoite surface
protein 1 (MSP-1), MSP-2, the apical membrane antigen 1,
etc., which are targets of the potentially protective immune
responses, are now being developed as candidates for vaccines
(reviewed in reference 22). However, a major problem in de-
veloping an effective vaccine is the high degree of genetic
diversity and antigenic variation found in the target antigens
(5, 9, 27, 29, 35, 40). This problem is further aggravated by the
fact that in several cases, these variant regions constitute im-
munodominant determinants with the potential to divert im-
mune responses from critical epitopes and/or obstruct matu-
ration of high-affinity antibodies to these epitopes (2, 3, 15).
These critical epitopes might represent structures involved in
some important processes, such as the merozoite invasion,
which is a crucial event in the life cycle of the parasite and are,
hence, rather conserved. For example, MSP-1 of P. falciparum
has several blocks which display a high degree of polymor-
phism among various strains of the parasite (reviewed in ref-
erence 29). However, its C-terminal region, termed MSP-119,
with its epidermal growth factor-like domains, is essentially
conserved even across the species, and it is this region that has
been shown to be critically implicated in the merozoite inva-
sion of erythrocytes (6, 7, 20). Similarly, a highly conserved
region II motif present in the circumsporozoite protein of all
Plasmodium species sequenced so far seems to play an essen-
tial role in the sporozoite invasion of hepatocytes (11, 30). In
fact, we (12), as well as others (36), have shown that immuni-
zation with synthetic peptides modeling highly conserved re-
gions of the P. falciparum antigens can even protect mice
against live challenge with the murine malaria parasites, viz.,
P. berghei or P. yoelii. Such conserved portions of malarial pro-
teins are currently the subject of active investigation as puta-
tive vaccine molecules.
The antigen which contains repeats of acidic and basic res-
idues (ABRA) of P. falciparum (41) seems to be another such
highly conserved molecule. It is a 101-kDa protein located on
the surface of merozoites as well as in the parasitophorous
vacuole within the infected erythrocytes (14, 46). Significantly,
this protein is also present in the immune clusters of merozo-
ites which are formed at the time of rupture of mature schi-
zonts in the presence of immune serum. Formation of such
clusters prevents the dispersal of merozoites, resulting in a
marked decrease in parasitemia, which is considered an indi-
cator of protective immunity (17, 28). Furthermore, ABRA is
almost fully conserved among various laboratory isolates of
P. falciparum (46), possesses a chymotrypsin-like activity (33),
and has a partial protein sequence homology with an extracel-
lular cysteine protease of another protozoan, Trichomonas
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vaginalis (16). All these findings about ABRA seem to indicate
its potential role in a protease-mediated process(es), such as
merozoite invasion of erythrocytes, which is a critical event in
the life cycle of the parasite. Because of its location on the
merozoite surface, its presence in the immune clusters of
merozoites, its highly conserved sequence, and its reported
protease activity, ABRA represents an attractive molecule for
development as a vaccine candidate.
In the present study, we have attempted to delineate the
putative epitopic sequences of ABRA by using a battery of
eight synthetic peptides based on its most hydrophilic regions
and its repeat sequences. We found that these sequences rep-
resented target epitopes for the serum immunoglobulin G
(IgG) antibodies in a large proportion of humans recovering
from P. falciparum infection. They also stimulated the periph-
eral blood mononuclear cells from convalescing patients from
an area of endemicity. Our results indicated that five out of six
sequences from the nonrepetitive regions and one of the two
repeat sequences elicited a boostable, IgG-type antibody re-
sponse in rabbits immunized with the carrier-free peptides. We
also found that antibodies against two of the peptides, both
nonrepetitive, exerted a strong inhibitory effect on the mero-
zoite invasion of erythrocytes, indicating the importance of
these constructs in inducing a potentially protective antibody
response.
MATERIALS AND METHODS
Parasite. The FID-3 isolate of P. falciparum was maintained in continuous
culture essentially according to the methods described by Trager and Jensen
(42), and a detergent-soluble extract of the parasite proteins was prepared as
described previously (38) for use as the antigen in the enzyme-linked immu-
nosorbent assay (ELISA) or the immunoblotting assay. A schizont-rich prepa-
ration of the parasites was also used to obtain genomic DNA by phenol-chloro-
form extraction and ethanol precipitation following standard procedures. The
quality and yield of genomic DNA was ascertained by agarose gel electrophore-
sis; this DNA was used to obtain the full-length ABRA-encoding gene and its
various fragments by amplification using PCR as described below.
Synthetic peptides. Analysis of the predicted amino acid sequence of ABRA
(46) according to the Chou-Fasman algorithm revealed six stretches, ranging
from 12 to 18 residues, having a hydrophilicity score of 40% or more. These
sequences are as follows (amino acid numbers are according to the numbering
system of Weber and colleagues [46]): AB-1, 19NIISCNKNDKNQ30; AB-2,
99ANNSANNGKKNNAEE113; AB-3, 395YKAYVSYKKRKAQEK409; AB-4,
448LKNKIFPKKKEDNQAVDT465; AB-5, 518VPPTQSKKKNKNET531; and
AB-6, 639ENDVLNQETEEEMEK653. In addition, two more constructs, repre-
senting the repetitive sequences in ABRA, were also synthesized: AB-7, TNDE
EDTNDEEDTNDEED, and AB-8, KEEKE EKEEKEEKEKEKE. The proce-
dures employed for synthesis, purification, and characterization of the synthetic
constructs AB-1 to AB-8 were essentially the same as those described in our
earlier work (24, 37, 38). Briefly, peptides were synthesized by stepwise solid-
phase synthesis in an automated peptide synthesizer (model 430A; Applied
Biosystems, Foster City, Calif.) and purified by gel filtration followed by reverse-
phase high-performance liquid chromatography. The purity and authenticity of
the synthetic peptides were ascertained by reverse-phase analytical high-perfor-
mance liquid chromatography and amino acid analysis, respectively.
Recombinant ABRA constructs. The full-length ABRA gene (but lacking an
N-terminal putative signal sequence) and its three major fragments were ampli-
fied from the parasite genomic DNA by PCR and cloned in Escherichia coli by
standard molecular biology protocols. Briefly, the ABRA gene encoding amino
acids (aa) 23 to 743, i.e., the full-length protein except for the putative signal
sequence, was amplified by PCR using the P. falciparum genomic DNA as the
template. A forward primer (59-CGGGATCCCGATGAACATG-39) represent-
ing the N-terminal region and incorporating a BamHI restriction site and a
reverse primer (59-AACCCAAGCTTATTTTGATTCTTCAG-39) representing
the C terminus and incorporating a HindIII restriction site were used for this
amplification reaction. The amplified DNA fragment (;2.1 kb) was cloned into
pGEMT vector (Promega Corporation, Madison, Wis.), and the nucleotide se-
quence of the cloned gene was partially determined by the dideoxynucleotide
chain termination method.
For recombinant protein expression in bacteria, E. coli, the ABRA gene was
divided into three regions (Fig. 1), the 59 region (AB-N) encoding the amino-
terminal portion of the protein (aa 23 to 370), which contained the hexapeptide
repeats; the middle region (AB-M) corresponding to the repeatless portion of
the protein (aa 371 to 510); and the 39 region (AB-C) encoding the carboxyl-
terminal portion of the protein (aa 511 to 743), which contained the KE and
KEE repeats (Fig. 1). These three fragments were amplified by using the high-
fidelity Pfu DNA polymerase enzyme and the recombinant plasmid DNA iso-
lated from the pGEMT clone of ABRA as the template and were subcloned as
BamHI-HindIII fragments in pMal vector (New England Biolabs, Inc., Beverly,
Mass.) for expression as a fusion protein with the maltose-binding protein.
To study the protein expression from these clones, E. coli cells (strain TB-1)
carrying the recombinant plasmids were grown overnight at 37°C in Luria broth
containing ampicillin. The overnight cultures were diluted 10-fold and incubated
at 37°C to an optical density at 600 nm (OD600) of 0.7 to 0.8 when protein
expression was induced with 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG)
for 2 h at 37°C. The cells were harvested and resuspended in lysis buffer (10 mM
phosphate, 30 mM NaCl, 0.25% Tween 20, 10 mM b-mercaptoethanol, 10 mM
EDTA, 10 mM EGTA). These cells were subjected to two cycles of freeze-thaw
treatment, followed by ultrasonication. After centrifugation of the sonicated
extract, an aliquot of the supernatant was analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and probed with rabbit anti-
peptide sera specific for each fragment.
Human samples. Serum samples were collected from eight normal, healthy
individuals who had no known past history of malaria and were negative for
malaria by slide examination at the time of drawing blood (24). With the P. fal-
ciparum lysate used as the capture antigen, these sera (each diluted 1/200)
yielded an average OD490 of 0.35 with a standard deviation of 0.05 (0.35 6 0.05)
by ELISA. With the synthetic constructs in the same assay, these sera gave
average OD490s of 0.10 6 0.02, 0.15 6 0.02, 0.13 6 0.03, 0.19 6 0.05, 0.10 6 0.02,
0.14 6 0.04, 0.10 6 0.01, and 0.2 6 0.04 with AB-1 to AB-8, respectively.
Sera were also collected from 50 patients, positive for P. falciparum malaria by
slide examination, admitted to the medical wards of Rabindra Nath Tagore
Medical College and Associated Hospitals, Udaipur (Rajasthan), India (24). All
these patients presented with characteristic symptoms of high fever, chill, and
rigor; a majority of them also had a previous history of fever of undetermined
etiology. All but one of these patients were successfully cured following treat-
ment with the standard regimen of chloroquine (at 600, 600, and 300 mg on days
1, 2, and 3, respectively). One patient that did not respond to chloroquine was
subsequently cured with a single dose of sulfalene (1,000 mg) plus pyrimeth-
amine (50 mg). Blood for serum collection from these patients was generally
obtained 1 day after the completion of drug treatment (24).
In addition, peripheral blood samples from 11 P. falciparum-infected patients
who had recovered from their last malaria episodes about 4 to 5 weeks prior to
the study and were malaria negative upon slide examination at the time of
sample collection and five normal, healthy individuals malaria negative by slide
examination were also collected for the lymphocyte transformation assay as
described below.
Informed consent from all the human subjects was obtained after explaining to
them the objectives of the present study in detail, particularly emphasizing the
fact that the results of this study might not be of any direct benefit to them. The
protocol for this study was approved by the institutional Human Volunteers
Research Ethical Committees of the two participating institutes, viz., the Inter-
national Center for Genetic Engineering and Biotechnology, New Delhi, India,
and the Malaria Research Centre (Indian Council of Medical Research), Delhi,
India.
FIG. 1. Schematic representation of P. falciparum ABRA and its three frag-
ments obtained by PCR amplification of the parasite genomic DNA and ex-
pressed as recombinant proteins as described in Materials and Methods. The
small, numbered horizontal bars indicate the positions of the sequences chosen
for synthetic peptides AB-1 to AB-8 as described in Materials and Methods. ss,
signal sequence.
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Lymphocyte proliferation assay. Peripheral blood samples were collected from
human volunteers who were living in an area of endemicity, had suffered from
confirmed P. falciparum malaria infection several months prior to the study, and
had been cured with the standard chloroquine regimen. They were malaria
negative by slide examination at the time of sample collection and gave informed
consent to participate in the study. Of 18 subjects approached, only 11 agreed to
give a blood sample for this part of the study. The peripheral blood mononuclear
cells (PBMC) were separated by centrifuging each of the blood samples on a
density gradient (Histopaque-1077; Sigma Chemical Co., St. Louis, Mo.). The
lymphocyte proliferation assay was set up in the 96-well tissue culture plates
(catalog no. 3595; Costar Scientific Corp., Cambridge, Mass.) with PBMC cul-
tured in RPM 1640 medium supplemented with 25 mM HEPES, 0.2% sodium
bicarbonate, 50 mM b-mercaptoethanol, 1.0 mM pyruvic acid, and 10% pooled
human serum (AB/Rh1 group). Seven of eight ABRA constructs were used at
three doses each, i.e., 10, 1.0, and 0.1 mg/well, with each well containing the cell
suspension in a total volume of 200 ml. Each dose was tested in triplicate wells;
concanavalin A, at a previously determined optimal concentration of 1 mg/well,
was used as a nonspecific, polyclonal mitogen. On day 3 (concanavalin A) or day
5 (peptide), cultures were pulsed with [methyl-3H]thymidine (0.5 mCi/well; Am-
ersham International plc, Little Chalfont, Buckinghamshire, England) for 6 h.
The cells were then harvested onto glass fiber filters by using the PHD cell
harvester (Cambridge Technology, Inc., Watertown, Mass.), and the 3H incor-
poration was determined by b-emission liquid scintillation spectroscopy. The
results were expressed as stimulation indexes (SIs); the SI represents the ratio of
counts per minute obtained in the presence of the peptide to those obtained in
the absence of the peptide.
Animals and their immunization. Animals used in this study were procured
from the Small Animal Facility of the National Institute of Immunology, New
Delhi, India. Animals were housed, fed, and used in the experiments following
guidelines set forth in the National Institutes of Health manual Guide for the
Care and Use of Laboratory Animals (30a).
Rabbits (New Zealand White; about 2 kg each) were immunized with a dose
of 200 mg of the carrier-free peptides emulsified in complete Freund’s adjuvant
and injected subcutaneously at multiple sites in the nuchal region, and on day 28
they received boosters containing a similar dose of the respective peptide emul-
sified in incomplete Freund’s adjuvant. Sera were collected from these rabbits on
days 0, 14, 28, 42, and 56, heat inactivated at 56°C, and stored at 220°C. Peptides
which failed to elicit a significant antibody response after the booster injection,
i.e., AB-2, AB-6, and AB-7, were inoculated once more on day 42 at a dose of 200
mg each. Sera were tested for the presence of antipeptide antibodies by an
ELISA using respective carrier-free peptides as the capture antigens.
Both preimmune and immune rabbit sera were adsorbed with fresh, washed,
normal human erythrocyte ghosts and then were dialyzed against chilled and
sterile phosphate-buffered saline (PBS) (0.15 M; pH 7.2) before being tested for
the presence of antiparasite antibodies in various assays.
For some experiments, IgG fractions were purified from preimmune and
immune rabbit sera by ammonium sulfate precipitation of the sera to obtain the
gamma globulin fraction followed by ion-exchange chromatography on an
Econo-Pac IgG purification column (Bio-Rad Laboratories, Richmond, Calif.) as
described previously (38). After their purity was ascertained by SDS-PAGE and
immunoblotting, the purified IgG fractions were dialyzed against plain RPMI
1640 medium, i.e., the medium supplemented with 25 mM HEPES and 0.2%
sodium bicarbonate but without serum, passed through sterile 0.22-mm-pore-size
membrane filters, and used in the merozoite invasion inhibition assays.
Purified IgG fractions obtained from serum samples from a rabbit immunized
with an 18-residue peptide sequence conserved in thrombospondin-related anon-
ymous protein and circumsporozoite protein of the parasite, previously shown to
exert a dose-dependent inhibitory effect on the P. falciparum merozoite reinva-
sion of human erythrocytes (38), were also included as positive controls in some
experiments as described below. Serum samples from another rabbit immunized
with P-8, a 21-mer synthetic peptide construct based on P. falciparum MSP-1 (24,
38), were also used as negative controls in some assays.
ELISA. Sera were tested for the presence of antibodies in an ELISA, using
carrier-free peptides or parasite lysate as the capture antigen. Procedures em-
ployed for the preparation of the parasite lysate (FID-3 isolate of P. falciparum)
and for performing the assay were essentially as described previously (24, 38).
Briefly, wells of flat-bottom Immulon-2 plates (Dynatech Laboratories Inc.,
Chantilly, Va.) were coated with the previously determined optimal concentra-
tion of capture antigen (carrier-free synthetic peptides or parasite lysate); the
uncovered reactive sites were blocked with 5% milk powder solution in PBS. The
antigen-coated wells were then sequentially incubated with appropriate dilutions
of the first antibody followed by optimally diluted, enzyme-labeled secondary
antibody (horseradish peroxidase-labeled anti-human or anti-rabbit IgG), with
thorough washing of plates in between the incubations. The enzyme reaction was
developed with o-phenylenediamine dihydrochloride as the chromogen and hy-
drogen peroxide as the substrate. After stopping the reaction with sulfuric acid,
the OD490 of the reaction product in the wells was recorded by using a Micro-
plate Reader (Molecular Devices, Palo Alto, Calif.). In an ELISA using parasite
lysate as the capture antigen, P. falciparum patient sera giving an OD490 of 0.2 or
more than the average mean OD490 obtained with the normal sera (i.e., an OD
of $0.55) were defined as positive sera. We realize that this arbitrary cutoff OD
value of 0.55 is rather high, but it ensures stringent specificity against background
noise in the sera from a region of endemicity like India. The same criterion of the
difference between OD values (DOD) being $0.2 was applied to determine the
specific positivity of clinical sera against the individual ABRA peptides. In the
end point titrations, the last dilution of a test serum yielding an OD490 twice or
more than twice that obtained with the respective preimmune serum (diluted
1/100) was taken as the end point titer.
Immunoblotting. The reactivity of the rabbit antipeptide sera with the parasite
protein(s) was further ascertained by immunoblotting. The whole parasite lysate
was fractionated on a 10% gel by SDS-PAGE under reducing conditions and
transferred onto a nitrocellulose membrane following standard procedures. Af-
ter the uncovered reactive sites of the nitrocellulose membrane were blocked by
saturation with 5% nonfat milk powder solution in PBS overnight, the membrane
was probed with various preimmune and immune rabbit sera by using a Mini
Protean II Multi-Screen apparatus (Bio-Rad Laboratories). Total lysates of
bacteria expressing the recombinant fragments of ABRA, viz., AB-N, AB-M, and
AB-C, were also similarly fractionated and probed with the respective region-
specific rabbit antibody, i.e., anti-AB-1, anti-AB-3, and anti-AB-8 antisera, re-
spectively. The parasite proteins and the recombinant ABRA fragments in the
bacterial lysates, separated by SDS-PAGE and transferred onto nitrocellulose
paper, were incubated first with rabbit antipeptide sera and then with the horse-
radish peroxidase-labeled anti-rabbit IgG antibodies. The final enzyme reaction
was developed with H2O2 as the substrate and 4-chloro-1-naphthol as the chro-
mogen.
Immunofluorescence assay. Sera from rabbits immunized with ABRA con-
structs were tested for their reactivity with the authentic parasite protein(s) in the
immunofluorescence assay as well (38). All rabbit sera were preadsorbed with
fresh human erythrocytes so as to get rid of any heterophile antibody possibly
present in these sera (38). Multispot antigen slides were made from a parasite-
infected erythrocyte suspension prepared from an asynchronous culture of P. fal-
ciparum (strain FID-3). The antigen spots, air dried and fixed with the acetone-
methanol (9:1, vol/vol) mixture, were sequentially incubated with serial dilutions
of the test sera and the optimally diluted fluorescein isothiocyanate-labeled
anti-rabbit IgG solution. The slides were finally mounted in the buffered glycerol
containing p-phenylenediamine dihydrochloride (1 mg/ml) as the antifading re-
agent and examined under a fluorescence microscope (Wild Leitz GmbH, Wet-
zlar, Germany), alternately in visible and UV light, to see specific binding of the
antibody to the parasite.
Merozoite invasion inhibition assay. The in vitro cultures of the FID-3 strain
of P. falciparum were synchronized at the ring stage by two treatments with 5%
sorbitol solution (25) and incubated further for about 30 h, so that at the time of
setting up of the assay, nearly 90% of the parasites were .4N segmenters. The
cultures were grown in RPMI 1640 medium supplemented with 10% human
serum plus 5% normal (preimmune) or immune rabbit serum and incubated in
a candle jar at 37°C for 20 h. Additional controls included culture wells with no
rabbit serum, wells with rabbit anti-P-8(MSP-1) serum (negative control [38]), and
wells containing rabbit anti-18-mer(conserved TRAP motif) total immune IgG at a
concentration known to cause 50% inhibition of the merozoite invasion in this
assay (38). In each experiment was included a parallel set of culture wells with
appropriate rabbit sera, monitored every 2 to 3 h by microscopy for any possible
toxic effect of these sera on the parasite or parasitized erythrocytes. At the end
of the assay, smears were drawn from aliquots taken from each well, stained with
Giemsa stain, and examined under a microscope by two researchers; only the
ring-infected cells were counted as parasitized cells for calculating percent par-
asitemia (number of parasitized erythrocytes out of a total of 100 erythrocytes);
at least 10,000 cells were counted to determine the level of parasitemia in each
smear. In a subsequent experiment, various concentrations of the purified IgG
fractions isolated from preimmune and immune rabbit sera were also incorpo-
rated in the test system.
RESULTS
Immunogenicity of synthetic ABRA peptides. We synthe-
sized six nonrepetitive sequence peptides based on their high
hydrophilicity score, potentially facilitating their accessibility to
the immune system and, in addition, two more constructs mod-
eling the repeat regions of ABRA. In an ELISA for measuring
levels of circulating IgG antibodies, we found that each of
these eight constructs bound appreciable amounts of antipara-
site antibodies in the sera from a large proportion of human
subjects recovering from natural P. falciparum infection (Fig.
2). Of 50 such sera that we tested, 33 (66%) yielded a positive
ELISA reaction with one or more ABRA constructs; of these
33 positive samples, we found that only 3 reacted with all eight
of the constructs, 6 reacted with seven constructs, 5 reacted
with six constructs, 3 reacted with five constructs, 2 each re-
acted with four, three, and two constructs, and 10 reacted with
only one of the eight constructs. Synthetic construct AB-3 was
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by far the most frequently recognized epitopic sequence, since
as many as 50% of the clinical samples bound to this peptide,
and as a group, the positive samples also yielded the highest
average DOD490 value (0.56 6 0.41) in the peptide ELISA,
while AB-1, which was recognized by 36% of these sera in the
same assay yielded the lowest average DOD490 value (0.31 6
0.09). We found four samples to be negative for both parasite-
and peptide-specific antibodies in this assay. Two other sam-
ples which were seronegative for the parasite antigen yielded a
positive ELISA reaction with one (AB-3) and two peptides
(AB-2 and AB-6), respectively.
In order to ascertain their putative potential to elicit T-cell
reactivity in humans, we tested these peptides in a lymphocyte
proliferation assay using PBMC obtained from humans who
had recovered from a recent malaria infection. Results of this
assay are summarized in Table 1. We have taken an SI of 2 or
more to indicate a positive result; in Table 1, we have pre-
sented only the positive results obtained in this assay. The
proliferative response made by PBMC from five normal,
healthy controls was uniformly poor to negligible. For four of
these patients, the values obtained in the unstimulated cultures
were 283 6 38, 652 6 276, 299 6 58, and 295 6 36 cpm and the
corresponding highest values following stimulation with any
ABRA construct were 550 6 111, 744 6 172, 390 6 72, and
296 6 24 cpm; in terms of the SI, these values represented
negative results (SI , 2). In the remaining one normal subject,
the unstimulated cultures gave a value of 774 6 48 cpm and the
corresponding highest value obtained was 1,875 6 488 cpm,
with AB-3, yielding an SI of 2.4; with all other constructs, SIs
below 2 were obtained. As evident from the data we have
provided in Table 1, most of the peptides worked optimally at
a dose of 1 mg/well in this assay. We found that AB-1 and AB-3
induced generally high levels of lymphoproliferation in almost
all 11 subjects tested, with SIs ranging from ,2 (in only one
case) to 16.91 (Table 1); two more peptides, AB-4 and AB-5,
were also found to elicit a strong proliferation response in 3 of
11 subjects each, with SIs varying from 2.4 to 19.76 (Table 1).
The proliferative responses obtained with other peptide con-
structs were below the threshold of positivity; the AB-8 pep-
tide, which represents a tandem repeat of KEE and KE,
proved to be the most ineffective T epitope in this assay (data
not presented).
Having ascertained that our synthetic constructs, indeed,
represented targets of the human immune response generated
during natural malaria infection, we proceeded to assess these
as carrier-free immunogens in experimental laboratory ani-
mals. As evident from the results presented in Fig. 3, five of the
six nonrepetitive peptides, viz., AB-1, AB-3, AB-4, AB-5, and
AB-6, when injected into rabbits, elicited a boostable IgG
antibody response with high titers persisting for several weeks
after the last immunization. One of the two repetitive sequence
peptides, i.e., AB-8, also induced a similar response. However,
the remaining two constructs, namely, AB-2 and AB-7, did not
stimulate any detectable antibody response even after another
booster.
Cross-reactivity of antipeptide sera with parasite protein(s)
and recombinant ABRA constructs. Furthermore, rabbit anti-
bodies generated against synthetic peptides also cross-reacted
with the native parasite protein in three different assays. Re-
sults of an ELISA using parasite lysate as the capture antigen
are presented in Fig. 4. Although the general pattern of the
time course of antibody reactivity with the parasite lysate an-
tigen was comparable to that obtained with the peptides used
as capture antigens (Fig. 3), the level of reactivity with the
parasite antigen was predictably low but well within the range
expected of antibodies raised with short, carrier-free peptide
immunogens (38). A careful analysis of data obtained with the
preimmune (week 0) and test (week 8) sera revealed that in the
hierarchy of responses obtained with the peptide ELISA (Fig.
3), AB-6, with an OD of test serum/OD of preimmune serum
ratio (T/P ratio) of 44.5, ranked at the top, followed by AB-4
(T/P ratio, 39.2), AB-8, AB-1, AB-5, and AB-3; as mentioned
earlier, the remaining two peptides, AB-2 and AB-7, induced
barely detectable levels of antibody response, their T/P ratios
FIG. 2. Distribution profile of antibody levels obtained by ELISA using sera
from 50 clinical malaria patients. Each serum was diluted 1/200 and tested in
duplicate against each of the eight ABRA constructs. The DOD490 value was
obtained by subtracting the OD490 value given by a normal human serum pool
from that given by the respective clinical serum. Each data point represents a
mean of duplicate values. A DOD490 value of 0.2 or more was defined as positive.
The solid horizontal line in each column represents the mean DOD490 value. Pf
Ag, P. falciparum antigen.
TABLE 1. Lymphocyte proliferative responses in P. falciparum
patients determined with ABRA peptides as
stimulating antigens
Patient’s
age (yr)
Patient’s
sexa
Response in un-
stimulated cultures
(cpm [mean 6 SD])
Highest SI obtainedb
AB-1 AB-3 AB-4 AB-5
28 F 241 6 73 8.95 14.85 ,2 ,2
24 F 220 6 66 ,2 2.40c ,2 ,2
35 M 283 6 54 3.38 10.04 ,2 ,2
20 M 815 6 123 7.14 5.20 3.52 5.36
15 M 459 6 115 7.80 4.70c ,2 ,2
16 M 364 6 248 4.91 6.90c 7.19c 2.40c
11 F 425 6 228 2.45 3.94 ,2 ,2
14 M 230 6 26 14.25 14.47 ,2 ,2
50 M 207 6 70 13.22c 16.91 11.80 19.76
22 F 272 6 41 5.09 5.20c ,2 ,2
12 F 363 6 68 4.16 8.60c ,2 ,2
a F, female; M, male.
b SI, counts per minute in stimulated cultures/counts per minute in unstimu-
lated cultures.
c Dose of stimulating peptide, 0.1 mg/well; all other values were obtained at a
1-mg/well dose of the respective peptide; responses observed with the remaining
ABRA peptides gave SIs which were all ,2 and, therefore, are not shown in this
table.
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being 3.25 and 2.75, respectively. With the parasite antigen
(Fig. 4), on the other hand, the highest T/P ratio (15.8) was
obtained with AB-3 followed by AB-1, AB-4, AB-6, and AB-5;
the T/P ratios obtained for the remaining sera were indicative
of marginal levels of antibody as detected in this assay. The
most notable feature of the results obtained in this assay was
the poor cross-reactivity of anti-AB-8 antibodies with the par-
asite antigen (T/P ratio, 1.9), in stark contrast to its very high
peptide-specific reactivity (T/P ratio, 27.71). In the immuno-
blot assay, all six of the high-titer, antipeptide sera cross-re-
acted with the parasite protein(s); thus, the rabbit antisera,
raised against AB-1, AB-3, AB-4, AB-5, AB-6, and AB-8, all
reacted with a parasite protein of the expected size, i.e., ;101
kDa (Fig. 5, lanes 9, 11 to 14, and 16, respectively); further-
more, sera against AB-1, AB-3, AB-4, and AB-5 also recog-
nized some additional protein bands of lower molecular weight
FIG. 3. Time course of IgG-type antibody responses generated in rabbits as monitored by an ELISA using homologous peptides as the capturing antigens. Rabbits
immunized with the carrier-free ABRA peptides received boosters at week 4 (solid arrow); animals immunized with AB-2, AB-6, and AB-7 received boosters one more
time at week 6 (broken arrow). Each serum was tested at a single dilution of 1/200 in duplicate wells.
FIG. 4. Cross-reactivity of rabbit antipeptide antibodies with the parasite protein(s) as monitored in an ELISA using parasite lysate prepared from the asexual blood
stages of P. falciparum as the capturing antigen. Each serum was tested at a single dilution of 1/200 in duplicate wells. See the legend to Fig. 3 for additional details.
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in the parasite lysate; we observed a rather weak recognition of
several parasite proteins, including one at ;101 kDa, with the
anti-AB-7 serum, which had shown virtually no antibody titer
in ELISAs with the peptide or the parasite lysate. As expected,
rabbit anti-AB-2 serum recognized no parasite protein in the
immunoblot assay; none of the rabbit preimmune sera reacted
with any parasite protein (Fig. 5, lanes 1 to 8).
In another immunoblot, rabbit sera against AB-1, AB-3, and
AB-8 strongly recognized the recombinant ABRA fragments
AB-N, AB-M, and AB-C, respectively, expressed as maltose-
binding protein fusion proteins in the IPTG-induced bacterial
cultures (Fig. 6, lanes I); these sera gave no such reaction with
the uninduced bacterial cultures. Although, these sera were
preadsorbed with bacterial lysates prepared from the host
E. coli strain lacking the specific inserts, their cross-reactivity
with some bacterial proteins persisted (Fig. 6).
The immunofluorescence assay (IFA) further established
the cross-reactivity of antipeptide sera with the parasite anti-
gen. The antibodies stained the trophozoites and the protein
present in the parasitophorous vacuole or even in the tubove-
sicular membrane network (Fig. 7A and B). Furthermore, an-
tibodies also seemed to stain merozoites within the mature
schizonts (Fig. 7C and D). This range of reactivity was
observed most notably with sera from rabbits immunized
with AB-1, AB-5, and AB-8, although all ELISA-positive
sera showed at least some reactivity in this assay, as apparent
from the IFA titers given in Table 2. However, we found no
strict correlation between the levels of seroreactivity we ob-
FIG. 5. Cross-reactivity of rabbit antipeptide sera with the parasite protein(s) in an immunoblot assay. The parasite proteins extracted from the asexual blood stages
of P. falciparum were separated on an SDS–10% PAGE gel, transferred onto a nitrocellulose membrane, and probed with different antipeptide sera by using a Bio-Rad
Mini Protean II Multi-Screen apparatus. Lanes 1 to 8 were probed with the preimmune sera, and lanes 9 to 16 were probed with the respective test sera. Thus, the
lanes are for sera as follows: 1 and 9, AB-1 sera; 2 and 10, AB-2 sera; 3 and 11, AB-3 sera; 4 and 12, AB-4 sera; 5 and 13, AB-5 sera; 6 and 14, AB-6 sera; 7 and 15,
AB-7 sera; and 8 and 16, AB-8 sera. Apart from the specific protein at approximately 101 kDa (arrow), some other bands were also detected, which may be degradation
products of ABRA.
FIG. 6. Three recombinant constructs representing the N-terminal region (AB-N), the middle region (AB-M), and the C-terminal region (AB-C) of ABRA were
expressed as recombinant fusion proteins in E. coli under conditions of IPTG induction (lanes I) and immunoblotted with rabbit anti-AB-1 (AB-1), anti-AB-3 (AB-3),
and anti-AB-8 (AB-8) sera. ABRA constructs of the expected sizes (arrows) were specifically recognized by the respective sera; no such reactivity was noticed in the
control, uninduced bacterial cultures (lanes U).
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tained by ELISA and by IFA. Thus, although the peptide
ELISA end point titers of AB-1, AB-5, and AB-8 were
1/12,800, 1/25,600, and 1/51,200, respectively, their IFA titers
(1/160) were similar (Table 2). It is pertinent to point out here
that in ELISA, sera were tested at twofold serial dilutions.
Therefore, although the three ELISA titers mentioned above
may seem to vary over a wide range, they actually fall within
merely three twofold serial dilutions.
Merozoite invasion inhibitory activity of the antipeptide
sera. Having established the immunogenicity of ABRA con-
structs in rabbits directly by immunization and in humans as
inferred from our immunological observations of the clinical
samples, we considered it logical to ascertain the biological
function, if any, of the peptide-specific antibodies. In order to
accomplish this, we tested the rabbit anti-peptide sera for ac-
tivity against the parasite in a growth inhibition assay. We
tested sera from only six rabbits that had shown positive anti-
body responses to six different ABRA constructs, as shown in
Fig. 3. The results of the merozoite invasion inhibition assay
are shown in Table 2. Surprisingly, the two sera, anti-AB-4 and
anti-AB-3, which had yielded the high parasite-specific ELISA
titers had only a marginal effect (anti-AB-3) or virtually no
effect (anti-AB-4) on the merozoite invasion of the erythro-
cytes; two other sera (anti-AB-6 and anti-AB-8) caused only
about 50% inhibition of invasion, while the remaining two sera
(anti-AB-1 and anti-AB-5), which had ELISA titers of only
1/12,800 and 1/25,600, respectively, inhibited the parasite in-
vasion by 94.4 and 77.6%, respectively (Table 2). That this
inhibition was, indeed, mediated through antibodies and not
any other serum component was further corroborated by the
results we obtained with purified IgG fractions from the pre-
FIG. 7. Immunofluorescence on air-dried, acetone-fixed monolayers of P. falciparum-infected erythrocytes (arrows) probed with rabbit anti-AB-1 serum. Shown are
a brightly fluorescent trophozoite (A and B) and merozoites (C and D) within a mature schizont seen under UV illumination (A and C) and visible light (B and D);
uninfected erythrocytes which did not react with antibody are also seen.
TABLE 2. Antiparasite activity in rabbit antipeptide sera
Immunogen
Peptide
ELISA
titer21
IFA
titer21
% Parasitemiaa
% Inhibi-
tionb
Preimmune
serum
(5%)
Immune
serum
(5%)
AB-1 12,800 160 2.13 6 0.11 0.12 6 0.06 94.3
AB-3 25,600 80 2.45 6 0.15 1.75 6 0.25 28.5
AB-4 102,400 40 2.18 6 0.07 2.18 6 0.11 0
AB-5 25,600 160 2.42 6 0.17 0.54 6 0.21 77.6
AB-6 102,400 80 2.49 6 0.16 1.16 6 0.16 53.4
AB-8 51,200 160 2.85 6 0.10 1.23 6 0.14 56.8
18-mer(TRAP)
c 25,600 160 2.11 6 0.06 0.97 6 0.23 54.0
P-8(MSP-1)
d 16,000 ND 2.44 6 0.22 2.14 6 0.26 12.3
a Parasitemia at 20 h is presented; percent parasitemia at 0 h was 0.23; data are
means 6 standard deviations obtained in triplicate wells for each serum in the
merozoite invasion inhibition assay.
b Percent inhibition in the merozoite invasion assay was calculated as [(%
parasitemia in preimmune serum 2 % parasitemia in immune serum)/% para-
sitemia in preimmune serum] 3 100.
c Positive control (38). Percent parasitemia is presented as that observed in the
presence of total IgG (600 mg/ml) from preimmune and immune rabbit sera.
d Negative control (37, 38).
TABLE 3. Inhibition of merozoite reinvasion of human
erythrocytes by rabbit antipeptide total IgG fractions
Immunogen Total IgG(mg/ml)
% Parasitemia (rings only)a
%
InhibitionPreimmune
IgG
Immune
IgG
AB-1 0.5 5.07 6 0.29 2.10 6 0.30 58.57
1.0 4.73 6 0.11 0.63 6 0.12 86.68
2.0 4.65 6 0.17 0.35 6 0.05 92.47
4.0 4.70 6 0.21 0.28 6 0.06 94.04
AB-5 0.5 4.65 6 0.27b 1.87 6 0.09 59.78
1.0 4.65 6 0.27b 1.07 6 0.11 76.98
2.0 4.65 6 0.27b 0.43 6 0.03 90.80
4.0 4.65 6 0.27b 0.28 6 0.04 93.98
AB-4 4.0 4.53 6 0.06 4.49 6 0.53 0.88
a Parasitemia at 20 h is presented; percent parasitemia at 0 h was 0.87; data are
means 6 standard deviations obtained in triplicate wells for each serum.
b Parasitemia obtained in the presence of rabbit preimmune IgG (0.5 to 4
mg/ml) was similar; therefore, the data from each of these sera was pooled to
obtain the best estimate of the mean.
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immune and immune rabbit sera in this assay. As apparent
from the data presented in Table 3, total immune IgG purified
from the sera of rabbits immunized with AB-1 or AB-5 exerted
an inhibitory effect on the in vitro merozoite invasion of eryth-
rocytes in a dose-dependent manner. In contrast, a similarly
purified IgG fraction from another rabbit, immunized with
AB-4 and showing high levels of peptide-specific antibodies
(Table 2), had no adverse effect on the merozoite invasion of
erythrocytes (Table 3).
DISCUSSION
Of several secretory proteins, such as the S antigen, the
serine-rich protein, the glycophorin binding protein, etc.,
which P. falciparum liberates during its asexual erythrocytic
cycle, ABRA alone shows virtually no polymorphism (23). In
fact, ABRA represents one of the most conserved antigenic
proteins of P. falciparum; in a comparative study of three
laboratory isolates of the parasite (namely, IMTM-22, FCR-3,
and Camp), Chulay and colleagues (14) observed little differ-
ence in the size of this protein. Moreover, genes encoding this
protein are nearly identical, with only four differences in the
ABRA nucleotide sequences from the two isolates FCR-3 and
Camp, which otherwise differ significantly in the sequence of
the serine-rich, 126-kDa protein (14, 45) as well as in the
molecular weights of several other proteins recognized by the
growth-inhibitory antibodies (13, 43). At the same time, no
protein analogous to ABRA from any other malarial parasite
has been described so far, nor has any strong homology be-
tween ABRA and any other housekeeping proteins been found
in the database search (45). These observations seem to un-
derline the uniqueness of this protein and its potentially sig-
nificant role in the biology of the parasite. In fact, there is
immunological as well as biochemical evidence to suggest the
possible involvement of ABRA in the processes of rupture of
mature schizonts, release of merozoites, and invasion of fresh
erythrocytes. In an elegant study, Nwagwu and colleagues (33)
demonstrated chymotrypsin-like proteinase activity associated
with the affinity-purified, parasite-derived ABRA protein.
Such a proteinase(s) has been implicated in the release of
mature merozoites from the parasitized erythrocytes and in the
merozoite invasion of fresh erythrocytes (4, 19, 26). ABRA
might well be one such proteinase. Thus, it represents an
attractive target for chemotherapeutic and immunological in-
tervention. However, there has not been any study on the
mapping of epitopic sequences in this protein and their possi-
ble immunogenicity and protectivity against the parasite.
We have, therefore, concentrated mainly on the hydrophilic
regions of the protein which, we reasoned, would be more
accessible for generating an antibody response. In the present
study, we have used eight synthetic peptides to delineate pu-
tatively protective epitopic sequences in ABRA. Our results
with the human sera tend to support our contention, since we
found that a majority of sera did contain appreciable levels of
antibodies directed against these sequences. It is of interest
that the synthetic construct AB-3 yielded the highest ELISA
positivity (50%) as well as the highest OD values for serum
samples tested. Furthermore, in a lymphocyte proliferation
assay with PBMC of human subjects, we found that four of
these constructs were recognized as T-helper-cell epitopes as
well. Interestingly, AB-1 and AB-3 elicited strong proliferation
responses in all 11 subjects tested (Table 1). Although we did
not determine the HLA haplotype of these patients, it seems
plausible that they represented more than one haplotype, and
to that extent, AB-1 and AB-3 appear to be degenerate in their
ability to bind to genetically restricted different HLA haplo-
types and stimulate T-cell responses. If that indeed is the case,
we would have two promiscuous T-helper-cell epitopes avail-
able from an asexual blood stage protein of the parasite. We
are currently looking into this possibility in greater detail in
both mice and humans.
It was encouraging to find that all eight constructs of ABRA
we synthesized for the present study indeed represented
epitopic targets of antibody responses generated during the
natural infections with P. falciparum (Fig. 2). But we realize
that the mere presence of circulating antibody in serum as
measured in an ELISA provides little information about the
possible protective potential of these sequences as immuno-
gens. It seemed to us quite pertinent to assess the immunoge-
nicity of these constructs in an experimental animal model and
to ascertain the potential antiparasite activity of the experi-
mentally raised, peptide-specific antibodies.
Interestingly, five of the six nonrepetitive sequences (AB-1
to AB-6) and one of the two repetitive sequences (AB-7 and
AB-8), without the use of any carrier protein, induced boost-
able, IgG-type antibody responses in rabbits (Fig. 3); only
AB-2 and AB-7 failed to generate any boostable antibody
response. The peptide-specific antibodies cross-reacted with
the parasite protein(s) in an ELISA (Fig. 4) and an IFA (Fig.
7). In an immunoblot also, rabbit anti-AB-5 serum recognized
a protein band at about 101 kDa and two more bands with
lower molecular masses, which could be the autoproteolytic
products of ABRA or cross-reactive epitopes present in other
proteins; a similar pattern of bands was seen with the rabbit
sera against other immunogenic ABRA constructs (Fig. 5). To
an extent defined by these results, the synthetic constructs
seem to mimic the portions of native protein faithfully enough
to induce antibodies which recognized the authentic parasite
protein in three different immunoassays. More significantly, we
found that antibodies to four synthetic constructs also exerted
antiparasite activity, causing 40 to 90% inhibition of the in
vitro merozoite invasion of erythrocytes with as little as 5%
antiserum incorporated in the culture system (Table 2). Al-
though it remains far from being fully established how anti-
bodies exert their influence upon the intracellular parasite,
several workers have used this assay as a suitable in vitro
correlate of potentially protective antibody (13, 34, 39, 43, 44).
In the case of ABRA, monoclonal antibodies have been dem-
onstrated to agglutinate freshly released merozoites, thus
preventing reinvasion of erythrocytes (14). Rabbit antibod-
ies which we raised against synthetic peptides modeling parts
of ABRA may also function in a similar way. However, it is also
likely that antibodies to ABRA or its parts might be working by
blocking its protease activity, which, along with other pro-
teases, is possibly involved in the secondary processing of
MSP-1, a process shown to be critical for producing invasive
merozoites (19).
Notwithstanding the apparent immunodominance of AB-3
in humans, as evident from the serological results (Fig. 2),
rabbit anti-AB-3 serum, though yielding a reasonably high
ELISA titer, was found to be poor in its direct antiparasite
activity; it caused only ;30% inhibition of the parasite in vitro;
similarly, AB-4-specific rabbit antibodies had virtually no di-
rect inhibitory effect on parasite growth. However, these neg-
ative results do not rule out the possibility of their growth-
inhibitory potential in cooperation with monocytes. In fact, a
number of studies investigating the importance and relevance
of this mechanism of parasite clearance have provided con-
vincing evidence for such a phenomenon occurring in malaria
(8, 10, 17, 18).
Synthetic peptides such as those evaluated in the present
study provide a promising alternative to conventional vaccines
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or those being produced by recombinant DNA technology. A
number of studies have demonstrated the feasibility of using
such constructs as potentially protective immunogens (1, 12).
In the first-ever human clinical trials of a synthetic peptide
vaccine, a polymeric, multicomponent malaria vaccine, SPf66,
has been found to be safe and immunogenic in both adults and
children residing in widely distant geographical regions with
different transmission rates (1, 31, 32), although its efficacy has
become a subject of controversy and contradiction (31, 32). At
the same time, results of these trials have underlined the need
to continuously search for other molecules and for better ways
to generate a protective immune response. Our present study,
which delineates a couple of putatively protective epitopes in
ABRA, represents only the first essential step in our ongoing
efforts to evaluate this protein as a possible vaccine candidate.
An important question would relate to the immunogenicity of
these peptide constructs in the context of different major his-
tocompatibility complex haplotypes on the one hand and var-
ious adjuvant formulations, other than Freund’s, on the other
hand. Studies have indicated that adjuvants could play a critical
role in determining the magnitude and specificity of immune
responses to a particular epitope(s) (21, 41a). We already have
preliminary data to indicate that AB-1 and AB-5 are recog-
nized in the context of several different major histocompatibil-
ity complex haplotypes of mice, although the titers of antibod-
ies were not very high (unpublished observations). Using
different adjuvant formulations, we are now in the process of
establishing the repertoire of humoral responses to ABRA in
terms of IgG subclasses of antibodies induced by various
ABRA constructs, the pattern of their affinity maturation for
the antigen, and their qualitative or functional features, such as
their growth-inhibitory or merozoite invasion-inhibitory poten-
tial.
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